Gut and Liver

The Korean Association for the Study of the Liver (대한간학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of Direct-Acting Antivirals in Patients with Hepatitis C Virus/Human Immunodeficiency Virus Coinfection: A Gap between Clinical Trial and Real Practice

  • Kim, Do Young (Department of Internal Medicine, Yonsei University College of Medicine)
  • Published : 2018.11.15
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012;308:370-378.
  2. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-459. https://doi.org/10.1056/NEJMoa032653
  3. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-2848. https://doi.org/10.1001/jama.292.23.2839
  4. Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:705-713. https://doi.org/10.1056/NEJMoa1501315
  5. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:714-725. https://doi.org/10.1056/NEJMoa1503153
  6. Wyles D, Brau N, Kottilil S, et al. Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase 3 study. Clin Infect Dis 2017;65:6-12. https://doi.org/10.1093/cid/cix260
  7. Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study. Clin Infect Dis 2018;67:1010-1017. https://doi.org/10.1093/cid/ciy220
  8. Neukam K, Morano-Amado LE, Rivero-Juarez A, et al. HIVcoinfected patients respond worse to direct-acting antiviralbased therapy against chronic hepatitis C in real life than HCVmonoinfected individuals: a prospective cohort study. HIV Clin Trials 2017;18:126-134. https://doi.org/10.1080/15284336.2017.1330801
  9. Gayam V, Hossain MR, Khalid M, et al. Real-world clinical efficacy and tolerability of direct-acting antivirals in hepatitis C monoinfection compared to hepatitis C/human immunodeficiency virus coinfection in a community care setting. Gut Liver 2018;12:694-703. https://doi.org/10.5009/gnl18004
  10. Montes ML, Olveira A, Ahumada A, et al. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection. AIDS 2017;31:1253-1260. https://doi.org/10.1097/QAD.0000000000001465